NASDAQ: ORGS - Orgenesis Inc.

Rentabilität für sechs Monate: +774.23%
Sektor: Healthcare

Aktionsplan Orgenesis Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient.

Weitere Details
The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Выручка 0.0333
EBITDA -0.0209
Число акций ао 0.0251 млрд
P/S 1.48
P/BV 8.11
EV/EBITDA -3.01
Цена ао 0.8511
ISIN US68619K2042
Сайт https://www.orgenesis.com
Валюта usd
IPO date 2012-03-12
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Preisänderung pro Tag: -2.97% (4.37)
Preisänderung pro Woche: -20% (5.3)
Preisänderung pro Monat: +613.8% (0.594)
Preisänderung über 3 Monate: +554.22% (0.6481)
Preisänderung über sechs Monate: +774.23% (0.485)
Preisänderung pro Jahr: +341.67% (0.96)
Preisänderung über 3 Jahre: -14.34% (4.95)
Preisänderung über 5 Jahre: -6.81% (4.55)
Preisänderung seit Jahresbeginn: +657.14% (0.56)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 268.68 1
P/BV -6.79 0
P/E 0 0
EV/EBITDA -3.04 0
Gesamt: 2.5

Effizienz

Name Bedeutung Grad
ROA, % -380.44 0
ROE, % 263.84 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.4165 10
Gesamt: 9.4

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -98.41 0
Rentabilität Ebitda, % 158.7 10
Rentabilität EPS, % 16.37 3
Gesamt: 4.6
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 924806 5.92
Knoll Capital Management, LLC 634738 4.06
Geode Capital Management, LLC 239264 1.53
Blackrock Inc. 127759 0.82
State Street Corporation 88659 0.57
Northern Trust Corporation 39122 0.25
Renaissance Technologies, LLC 38799 0.25
Bank Hapoalim B.M. 32052 0.21
Chapin Davis, Inc. 20000 0.13
Cambridge Investment Research Advisors Inc. 18330 0.12



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Ms. Vered Caplan M.Sc. Chairperson of the Board, CEO & President 341.38k 1969 (55 Jahre)
Prof. Sarah Ferber Ph.D. Founder & Chief Scientific Officer 268.32k 1954 (70 Jahre)
Dr. Shimon Hassin Ph.D. Chief Technology Officer N/A
Mr. Victor Miller CFO, Secretary & Treasurer N/A 1970 (54 Jahr)
Pierre Lammeretz Interim Chief Operating Officer N/A
Mr. Joseph Carpinelli Chief Financial Officer of Octomera N/A

Adresse: United States, Germantown. MD, 20271 Goldenrod Lane - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.orgenesis.com